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Abstract 
 
Background 
The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide 
chemotherapy in pre-clinical glioblastoma models but brain penetration was poor. Clinically, PARP 
inhibitors exacerbate the hematological side-effects of temozolomide. The OPARATIC trial was 
conducted to measure penetration of recurrent glioblastoma by olaparib, and assess the safety and 
tolerability of its combination with temozolomide.  
Methods 
Pre-clinical pharmacokinetic studies evaluated olaparib tissue distribution in rats and tumor-bearing 
mice. Adult patients with recurrent glioblastoma received various doses and schedules of olaparib 
and low-dose temozolomide in a 3+3 design. Suitable patients received olaparib prior to 
neurosurgical resection; olaparib concentrations in plasma, tumour core and tumour margin 
specimens were measured by mass spectrometry. A dose expansion cohort tested tolerability and 
efficacy of the recommended phase II dose (RP2D). Radiosensitizing effects of olaparib were 
measured by clonogenic survival in glioblastoma cell lines.  
Results 
Olaparib was a substrate for multi-drug resistance protein-1 and showed no brain penetration in rats 
but was detected in orthotopic glioblastoma xenografts. Clinically, olaparib was detected in 71/71 
tumor core specimens (27 patients, median 496nM) and 21/21 tumor margin specimens (9 patients, 
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median 512.3nM). Olaparib exacerbated TMZ-related hematological toxicity, necessitating 
intermittent dosing. RP2D was olaparib 150mg (3 days/week) with TMZ 75mg/m2 daily for 42 days. 
Fourteen (36%) of 39 evaluable patients were progression-free at 6 months. Olaparib radiosensitized 
six glioblastoma cell lines at clinically relevant concentrations of 100 and 500 nM. 
Conclusions 
Olaparib reliably penetrates recurrent glioblastoma at radiosensitizing concentrations, supporting 
further clinical development and highlighting the need for better pre-clinical models. 
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Importance of the Study 
 
 
Despite failing to cross the intact blood-brain barrier (BBB) in pre-clinical models, olaparib 
penetrated both tumor core and tumor margin regions of recurrent glioblastoma at concentrations 
similar to those observed in breast cancer patients. The novel observation that tumor margin 
concentrations of olaparib were similar to those in the tumor core indicates clinically significant 
enhancement of BBB permeability even in 5-ALA non-fluorescing regions of glioblastoma. Olaparib 
effectively radiosensitized six glioblastoma cell lines in vitro at the median tumor concentration 
(500nM) and the lower end of the tumor concentration range (100nM).  While olaparib exacerbated 
the hematological toxicity of temozolomide, as expected, intermittent dosing was tolerated. These 
observations support further clinical development of olaparib in glioblastoma in combination with 
radiation therapy and indicate that conventional pre-clinical models of the BBB do not predict 
clinical pharmacokinetics.  
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Introduction 
Improvements in outcomes for brain tumor patients have failed to match those for many 
extracranial cancers. Glioblastoma (GBM) is the most common malignant primary brain tumor and 
confers a poor prognosis, with average life expectancy being 12 – 18 months for patients undergoing 
neurosurgical resection followed by radiotherapy with concomitant and adjuvant temozolomide 
(TMZ) chemotherapy 1. Treatment options for recurrent GBM are particularly limited; recent 
randomised studies have yielded 6-month progression-free survival (PFS) rates of 18-35% and 
median overall survival durations of 9-10 months 2,3.  
 
Poor treatment outcomes have been attributed in part to the failure of systemic agents to penetrate 
brain tumours at therapeutic levels, for which the BBB has largely been held responsible 4. The BBB 
protects the central nervous system from toxic molecules in the blood through ultrastructural 
features that restrict paracellular diffusion of polar solutes, and efflux mechanisms that export 
substrate molecules. The human BBB expresses high levels of ATP-binding cassette (ABC) transporter 
proteins, notably P-glycoprotein (Pgp, also known as Multidrug Resistance Protein 1, MDR1) 5.  
 
Blood vessels in GBM are grossly abnormal, however, exhibiting microvascular proliferation and 
increased permeability 6,7, which cause florid contrast enhancement on magnetic resonance imaging 
(MRI). While BBB integrity is grossly disrupted in the contrast-enhancing ‘tumor core’ regions of 
GBM, the extent to which the BBB is compromised in marginal regions, which do not display contrast 
enhancement, is poorly understood.  Whereas most conventional cytotoxic drugs are large, polar 
molecules that do not penetrate GBM 8, the pharmacokinetic (PK) properties of ‘small molecule’ 
agents are likely to be more conducive to penetration of the dysfunctional BBB. At the moment, 
however, there is little clinical PK data with which to substantiate this theory. Small molecule 
treatments for GBM have been ineffective to date 9, but this may reflect lack of biological efficacy as 
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much as failure of drug penetration 10 11,12. Hence there is a need for detailed PK studies of candidate 
small molecule therapies in glioblastoma patients, which should characterize drug delivery to the 
tumor margins as well as the tumor core. 
 
Olaparib is an orally bioavailable small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), 
which contributes to repair of DNA damage induced by ionizing radiation (IR) and alkylating drugs 
including TMZ 13. While single agent activity of PARP inhibitors is restricted to tumors with defects in 
homologous recombination (HR) DNA repair 14,15, olaparib and other PARP inhibitors sensitize a 
broad spectrum of cancer cells to both IR and TMZ [28,29] and potentiate these agents in preclinical 
glioma models 16. PARP inhibitors also have vasodilatory effects that have been associated with 
increased drug delivery to tumours in pre-clinical models 17. Despite these promising preclinical data, 
clinical development of olaparib for GBM has been hampered by lack of PK information, the absence 
of a reliable pharmacodynamic (PD) biomarker of PARP inhibition, and the propensity of PARP 
inhibitors to exacerbate hematological side-effects of TMZ 18.  
 
The aims of this study were fourfold: pre-clinically, to measure penetration of the normal brain and 
orthotopic GBM xenografts by olaparib; clinically, to characterise olaparib PK in core (5-ALA 
fluorescing) and margin (5-ALA non-fluorescing) regions of recurrent GBM; to ascertain whether 
olaparib affects tumor perfusion and vascular permeability; and to assess the safety and tolerability 
of combining olaparib with a 42-day, daily low-dose TMZ regimen. This TMZ schedule was selected 
because it is given concomitantly with IR to patients with newly diagnosed GBM and represents the 
clinical ‘line of sight’ for the combination with olaparib. Having established the range of olaparib PK 
in patient specimens, we evaluated the radiosensitizing effects of these clinically relevant 
concentrations in established and patient-derived GBM cell lines.  
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Methods 
 
Pre-clinical methods  
Canine kidney epithelial cells, stably expressing human MDR1 cDNA (MDCKII-MDR1 cells) or empty 
vector (MDCKII control), were used to model the intact BBB and determine permeability coefficients 
of (14C)-olaparib in the presence of ketoconazole (25M). Whole body autoradiography was 
performed on male pigmented rats after single oral administration of [14C]-olaparib (15 mg/kg; 5 
MBq/kg). For autoradiography studies, animal care and experiments were carried out in accordance 
with AstraZeneca guidelines, which comply with UK standards. Olaparib PK was assessed in CD1 
nude mice bearing intracranial G7 GBM xenografts from which tumor, blood and contralateral brain 
specimens were taken and snap frozen 2, 5 and 24 hours after dosing (50 mg/kg). Olaparib 
concentrations were measured by mass spectrometry. Xenograft experiments were performed 
under the relevant UK Home Office Project Licence and carried out with ethical approval from the 
University of Glasgow under the Animal (Scientific Procedures) Act 1986 and the EU directive 2010. 
Mice were maintained in individually ventilated cages with environmental enrichment and ARRIVE 
guidelines followed. Radiosensitizing effects of olaparib (100 and 500 nM) were measured by 
clonogenic survival assay in established (T98G, UVW) and patient-derived cell lines (G7, E2, G1, R10). 
The linear quadratic model was fitted and integrated to determine mean inactivation dose (MID) for 
each condition and sensitizer enhancement ratios (SER) calculated as MID ratios between control 
and olaparib treatments. Ratiometric t-test analysis determined SER confidence intervals and P-
values. Further details are available in Supplementary Material.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noaa104/5826799 by guest on 29 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
9 
 
Clinical study population  
OPARATIC (NCT01390571) was a phase I study investigating the pharmacokinetics, safety and 
toxicity of olaparib in combination with TMZ in adult patients with recurrent GBM. Stage 1 was a 
pilot study to confirm tumour penetration; Stage 2 was divided into dose escalation and dose 
expansion cohorts.  
 
Eligible patients were aged ≥18 with WHO performance status 0-2 and had radiological evidence of 
recurrent GBM (RANO criteria) after primary treatment with chemoradiotherapy and adjuvant 
chemotherapy. Exclusion criteria included previous chemotherapy for recurrent GBM; radiotherapy, 
endocrine therapy or immunotherapy within 12 weeks, or chemotherapy or biological therapy 
within 4 weeks. Study investigations and treatments were approved by an NHS Research Ethics 
Committee in accordance with assurances approved by the UK Medicines and Health Regulatory 
Authority. Informed consent was obtained from each participant and data were anonymized. 
Isocitrate dehydrogenase (IDH) mutational status was not available for several of the patients 
(recruitment commenced in 2012, before IDH testing was routinely conducted) and IDH status was 
not an eligibility criterion. 
 
Study Design and Treatments  
Stage 1 patients received olaparib tablets 200mg twice daily for seven doses prior to resection of 
recurrent tumor. Stage 2 patients (dose escalation phase) received different doses and schedules of 
olaparib and TMZ for 42 days of each 56 day cycle using a 3+3 dose escalation design (Figure 2). Up 
to three cycles were delivered in the absence of disease progression or unacceptable toxicity. 
Patients progression-free after three cycles were eligible for further cycles if approved by sponsor. 
Neurosurgery was optional; patients undergoing resection received olaparib at the designated 
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cohort dose for at least three days prior to surgery (‘Cycle 0’). After post-operative recovery, 
patients received olaparib/TMZ according to cohort. Patients not undergoing resection received 
Cycle 0 then immediately started Cycle 1 of olaparib/TMZ. Neurosurgical resection was mandatory in 
the Expansion Cohort. 
 
Study Assessments and Trial Endpoints 
The primary endpoint of Stage 1 required olaparib to be detectable above the lower limit of 
quantification (LLQ) in at least one tumor specimen from up to six patients. At neurosurgery, 
contrast-enhancing tumor regions identified on pre-operative MRI scans were targeted for resection. 
Specimens were assessed by intraoperative cytology; three regions of viable, solid tumor from each 
patient were snap frozen for PK analysis by liquid chromatography mass spectrometry (LC-MS). In 
the Expansion Cohort, 5-ALA guided neurosurgery enabled discrimination of fluorescent ‘core’ tissue 
from non-fluorescent ‘margin’ tissue. Up to three tumor margin biopsies were taken from each 
patient, from each of which half was frozen for PK analysis and half fixed for histology. Blood and 
tumour specimens for PK analysis were taken 3 – 5 hours after the final pre-operative olaparib dose. 
 
The Stage 2 dose escalation primary endpoint was maximum tolerated dose (MTD) and schedule of 
olaparib/TMZ. Toxicity was defined using National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.02. If two or more of six patients at one dose level 
experienced a dose limiting toxicity (DLT) this was considered ‘not tolerated’ and designated the 
Maximum Administered Dose (MAD). Dose escalation and expansion decisions were influenced by 
the need for dose reductions of olaparib and TMZ as well as DLT’s as defined by the protocol. MTD 
was defined as either reduced dose or less frequent administration of olaparib than MAD and was 
further evaluated in the Dose Expansion cohort to generate the recommended phase II dose (RP2D). 
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Secondary endpoints included PFS at 6 months (PFS-6, assessed radiologically using the RANO 
criteria) and radiological measurement of BBB permeability and perfusion by diffusion weighted 
(DW) and dynamic contrast-enhanced (DCE) MRI. Patients underwent two baseline MRI scans 24 
hours apart before commencing olaparib and a third scan after at least three days of olaparib, prior 
to surgery. Further details of the imaging protocol are provided in the Supplementary Material. 
Confidence intervals for PFS data were calculated using the exact binomial distribution. 
 
Exploratory endpoints included correlation of tumor core and margin olaparib concentrations with 
plasma levels and histological and Immunohistochemical (IHC) features including H&E, Ki67, PARP-1 
and blood vessel density. Histopathological methods are provided in Supplementary Material. 
Additional GBM specimens for pilot poly(ADP-ribose) IHC studies were obtained from Brain Tumour 
Bank South West (Bristol, UK) with appropriate ethical approvals. 
 
Results 
 
Pre-clinical pharmacokinetic assessment of olaparib 
Data from MDCKII-MDR1 cells indicated that olaparib (1-10 µM) was a substrate for MDR1, with the 
MDR1 inhibitor ketoconazole reducing the apparent permeability of MDCKII-MDR1 cells to olaparib 
by 40 – 62% (Figure 1A, Supp. Tables 1 and 2). Whole body autoradiography of male and female rats 
after single dosing with [14C]-olaparib (15 mg/kg, 5 MBq/kg) revealed radioactivity to be 
undetectable in brain or spinal cord at any time-point (Figure1B, Supp. Figure 1; Supp. Table 3). In 
contrast, PK assessment of olaparib distribution in CD1 nude mice bearing intracranial G7 GBM 
xenografts revealed tumor penetration at the 2 hour timepoint in all four mice, with concentrations 
varying widely (Figure 1C; range 110-2780 nM, median 347 nM). Olaparib was detected at lower 
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levels in the contralateral (non-tumor bearing) cerebral hemisphere (range 53-114 nM, median 84 
nM) and plasma levels were approximately 4.5 fold higher than tumor levels (range 773-2826 nM, 
median 1592 nM). Plasma levels fell to approximately 15% by 5 hours (median 230 nM); olaparib 
was detectable in one tumor specimen at 5 hours and undetectable in the contralateral hemisphere 
at 5 and 24 hours. 
 
Patients  
48 patients were enrolled into the OPARATIC study: three in Stage 1, all of whom underwent 
surgery; 32 in the Dose Escalation phase of Stage 2, of whom 11 had surgery; and 13 in the Dose 
Expansion phase of Stage 2, of whom all had surgery. Ten of the thirteen Dose Expansion patients 
underwent 5-ALA guided resections and tumor margin sampling (Figure 2). Sixty percent of patients 
were female and median age was 51 years (range 18-68). All patients had received radiotherapy as 
first-line treatment, of whom 47 (98%) had received concurrent chemotherapy.  
 
Pharmacokinetic results 
Olaparib was detected in all nine samples from the three Stage 1 patients, triggering progression to 
Stage 2. The mean olaparib concentration in Stage 1 samples was 471nM (range 164-992 nM, Figure 
3A; 200 mg BD dose level). From the whole study population, 71 tumor core samples from the 27 
surgical patients were of sufficient mass for PK testing. Olaparib was detected in all 71 of these 
specimens with median concentration 496 nM (range 97-1374 nM), similar to breast cancer data 19. 
Whereas plasma olaparib levels were broadly dose-dependent (Figure 3A), tumor olaparib 
concentrations did not correlate with olaparib dose (Figure 3A) or plasma concentrations (Figure 3B). 
Ratios between tumor and plasma olaparib concentrations were highly variable (mean 0.25, range 
0.01 – 0.9).  
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Olaparib was also detected in all 21 tumor margin samples that were of sufficient mass for PK 
analysis. These samples were obtained from nine Dose Expansion patients (Figure 3C). The median 
tumor margin olaparib concentration was 512.3 nM (range 97-1237 nM) and for individual patients 
the mean ratio between margin and core concentrations was 1.08 (range 0.32 – 3.77).  
 
Sufficient tumor margin biopsy tissue for IHC analysis was available for eight patients, of whom six 
had sufficient material for all planned staining protocols. A specialist neuropathologist (KK) verified 
whether H&E stained sections represented genuine tumor margin material and estimated the 
proportion of tumor cells in each section. IHC staining for two putative tumor cell markers PARP-1 20 
and Ki67 was performed where possible, along with CD31 staining to identify blood vessels. Figure 
4A shows representative H&E, Ki67 and PARP-1 staining of tumor core and margin sections from one 
patient. Supplementary Table 4 shows IHC and olaparib data for each tumor margin specimen. Blood 
vessels accounted for less than 1% of tumor margin area in each section (mean 0.67%, range 0.01-
2.30%), and no correlation was observe  between olaparib concentrations and blood vessel area 
(R2=0.04, p=0.42; Figure 4Bi), indicating that the olaparib detected in these specimens was not 
intravascular. Olaparib PK values did not correlate with tumor cell density as measured by two 
surrogate tumor cell markers PARP-1 and Ki67 (Figure 4Bii and iii). 
 
Safety and tolerability of concurrent administration of olaparib and TMZ  
Thirty-nine patients (29 dose escalation, 10 dose expansion) were evaluable for safety. Cohort 1 was 
expanded to 6 patients because neutropenia (grade 3) and thrombocytopenia (grade 2) necessitated 
dose reductions in two patients. One DLT (grade 3 vomiting) required expansion of cohort 3. One 
patient in cohort 4 experienced toxic death associated with pancytopenia, septic shock and renal 
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failure. This schedule was not considered tolerable because most patients required dose reductions 
and/or discontinuations. For cohort 5, olaparib was de-escalated to 150 mg once daily (days 1-3 per 
week) with full dose TMZ (75 mg/m2); this was defined as the MTD and confirmed as the RP2D after 
evaluation in the Dose Expansion Cohort. Of 16 RP2D patients evaluable for toxicity, 7 experienced 
grade 3-4 hematological toxicities: anaemia (3), lymphopenia (7), thrombocytopenia (4) and 
neutropenia (2). None was complicated by sepsis or bleeding. Additional grade 2 adverse events in 
this cohort included pruritus (1), nausea (1) and vomiting (1). Adverse events are summarised in 
Table 1.  
 
Efficacy  
Of 36 patients evaluable for efficacy, 14 (39%, 95% CI: 23.1% to 56.5%) remained progression-free at 
6 months, of whom 9 were in Dose Escalation cohorts and 5 in the Dose Expansion cohort. Of 16 
evaluable RP2D patients, 10 received one cycle, 3 received 2 cycles, 2 received 3 cycles and 1 
received 5 cycles. Since most patients underwent neurosurgery prior to commencing study 
treatment, measurable disease was uncommon and radiological response was not a study endpoint. 
 
Imaging results  
Amongst Stage 1 and Dose Expansion patients, no significant changes in perfusion or permeability 
parameters were observed between baseline and post-olaparib scans (Supp. Figure 2). Marked 
changes were observed in one patient whose histology at resection revealed radiation necrosis 
rather than recurrent GBM. Average tumor core olaparib concentrations did not correlate with 
baseline imaging biomarkers, but a significant negative correlation was observed between the each 
patient’s highest olaparib concentration and the Ktrans value in their baseline scans (Supp. Figure 3A, 
R2=0.39), suggesting that higher olaparib concentrations were associated with low blood flow and/or 
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low endothelial permeability.  Maximum olaparib concentration also correlated negatively with vp 
(fractional plasma volume; R
2=0.28; Supp. Figure 3B), supporting our assertion that intravascular 
olaparib was not responsible for tumor drug levels.  
 
In vitro evaluation of radiosensitizing efficacy 
In pilot studies we determined that pharmacodynamic confirmation of PARP inhibition would not be 
possible in GBM patients because poly(ADP-ribose (PAR, the product of PARP activity) was 
essentially undetectable in untreated tumor specimens from five GBM patients that were obtained 
from a brain tumor biorepository (Supp Fig 4). In the absence of a robust PD biomarker for PARP 
inhibition, we wanted to assess the likely clinical activity of the olaparib concentrations achieved. 
The hematological toxicities associated with combined olaparib/TMZ therapy indicate that the most 
promising role for olaparib in GBM is in combination with radiation therapy. Having observed 
concentrations above 100 nM in nearly all specimens, and median tumor concentrations of around 
500 nM, we evaluated the radiosensitizing effects of 100 and 500 nM olaparib by clonogenic survival 
assay (Figure 5). Significant radiosensitisation at both concentrations was observed in six GBM cell 
lines, with SER values ranging from 1.1 to 1.7 (Supp. Table 5) and no dose response apparent within 
the range tested. 
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Discussion 
This study demonstrates unequivocally that olaparib penetrates tumor core and tumor margin 
regions of recurrent GBM, despite pre-clinical evidence indicating failure to penetrate the intact 
BBB. The absence of a robust PD biomarker of PARP inhibition together with the infeasibility of 
obtaining pre/post-olaparib tumor specimens in these patients made it impossible to rigorously 
assess the clinical activity of the drug concentrations achieved. However, olaparib levels were within 
the range of 100 to 1000 nM in all specimens, concentrations that achieved significant 
radiosensitisation in all six GBM cell lines tested. Combining olaparib with daily low-dose TMZ was 
safe and reasonably well tolerated, but intermittent olaparib dosing was required to mitigate 
hematological toxicity. The observed 6-month progression-free survival rate of 39% compares 
favourably with recent clinical trials but was deemed insufficient to support further development of 
the combination in this population. However, the resoundingly positive PK data have underpinned 
phase I and II studies of olaparib in combination with radiotherapy +/- TMZ in patients with newly 
diagnosed GBM 21. The modest activity of the olaparib-TMZ combination is at least partly 
attributable to the reduced olaparib dosing that was required to avoid severe hematological toxicity, 
and in our view should not be taken as evidence of inadequate tumor penetration by olaparib. 
 
This study provides the first direct evidence that a drug showing no penetration of the intact BBB in 
pre-clinical models penetrates GBM in patients at clinically meaningful concentrations. Indeed, 
olaparib penetrated tumor core and margin regions at concentrations similar to those observed in 
breast cancer specimens 19,22. Consistent with studies in other tumor types 19,22, no correlation was 
observed between tumor and plasma concentrations. While variability in the time between olaparib 
dosing and tumour sampling may have influenced these results, we propose that uptake and 
retention of olaparib in GBM is determined primarily by tumor vasculature characteristics. This is 
supported by DCE-MRI data showing an inverse correlation between tumor olaparib concentrations 
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and baseline Ktrans values. The in vitro radiosensitisation data presented here are consistent with an 
ex vivo study demonstrating >90% inhibition of PARP activity at 50 nM olaparib 23 and support the 
concept that meaningful radiosensitisation of GBM may be achievable with clinically deliverable 
olaparib doses. Our study also highlights the need for contemporaneous development of robust PD 
biomarkers during drug development for GBM and other brain tumours. 
 
To study tumor margin regions, neurosurgeons undertook 5-ALA guided resections to obtain 
macroscopic clearance of tumor tissue then sampled adjacent non-fluorescent tissue. These samples 
were confirmed as tumor margin material by histological analysis: the majority comprised less than 
5% tumor cells and only one represented solid tumor. Accurate quantification of tumor cell density 
was not possible because there are no validated tumor cell markers for IDH wild type GBM, but the 
surrogate tumor markers PARP-1 and Ki67 supported the histological evaluation. The highly novel 
finding that tumor margin olaparib concentrations were similar to those in core regions indicates 
that BBB integrity is compromised even in regions of GBM where tumor cells are sparse and MRI 
contrast enhancement is not observed. One possible explanation is that co-option of vessels by 
invading glioma cells enables small numbers of infiltrating tumor cells to disrupt BBB function, as 
recently demonstrated in orthotopic murine models 24.  
 
DCE-MRI investigations were performed to assess the impact of olaparib on tumor perfusion and 
identify candidate imaging biomarkers of olaparib PK. While olaparib did not reproducibly affect 
DCE-MRI parameters, a negative correlation between maximum tumor olaparib concentration and 
Ktrans was observed. We speculate that this reflects increased retention of olaparib within tumors 
with reduced blood flow and hence reduced drug washout. 
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Our findings have important implications for pre-clinical and clinical development of small molecule 
treatments for GBM and other brain tumors. They illustrate that the pre-clinical models currently 
used to measure BBB penetration fail to predict GBM penetration in patients, and motivate us to 
recommend direct measurement of GBM PK and PD in early phase evaluation of novel agents, in 
both core and margin regions of these tumors. Finally, our data support the need for more 
representative pre-clinical models of the ‘blood-tumor barrier’ to enable rational selection of 
compounds for development and clinical testing. 
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Figure Legends 
Figure 1: Pre-clinical pharmacokinetic assessment of olaparib. 
(A) Directional transport of olaparib across MDCKII cells stably expressing human MDR1 cDNA 
(MDCKII-MDR1) or empty vector (MDCKII control) was measured after 120 minutes incubation with 
1, 3 and 10 µM [14C]-olaparib alone or with 25 µM ketoconazole. Apparent permeability coefficients 
were calculated for apical to basolateral (Papp a – b) and basolateral to apical transport (Papp b – a) as 
described in Methods. Olaparib efflux was shown to require expression of MDR1 and to be reduced 
by the MDR1 inhibitor ketoconazole. (B) Single oral doses of 15 mg/kg [14C]-olaparib were 
administered to male pigmented rats that were subsequently culled, sectioned and subjected to 
whole body autoradiography at the timepoints shown. Radioactivity was excluded from the central 
nervous system in all animals at all timepoints. (C) Twelve weeks after intracranial implantation of 
G7 glioblastoma xenografts, CD1 nude mice were dosed with olaparib (50 mg/kg) by oral gavage. 
Blood, tumor and contralateral (non tumor bearing) brain were harvested and snap frozen at the 
time points shown. Olaparib levels were measured by mass spectrometry (Pharmidex) and are 
shown as dotplots with horizontal bars representing median values (n ≥ 3 for each timepoint). Note 
different y-axis scales. 
 
Figure 2: CONSORT diagram of OPARATIC study design and patient disposition. 
 
Figure 3: Clinical pharmacokinetic assessment of olaparib. 
 (A) Mean olaparib concentrations in tumour core and plasma samples from patients grouped 
according to dose of olaparib received in cycle 0 (pre-surgery). 100 mg QD, n=10; 150 mg QD, n=35; 
200 mg BID, n=3. (B) Mean olaparib concentrations in tumour core specimens plotted against mean 
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plasma olaparib concentrations in 27 patients undergoing surgical resection. (C) Mean olaparib 
concentrations in tumour margin specimens plotted against mean tumour core concentrations in 9  
patients in the Dose Expansion Cohort. All measurements performed by LC-MS. 
 
Figure 4: Immunohistochemical analysis of OPARATIC tumour specimens. 
 (A) Representative images of histological sections obtained from a single patient in the Dose 
Expansion Cohort: H&E (x20) of (i) tumour core and (ii) tumour margin (<3% tumour cell infiltrate); 
Ki67 immunohistochemistry (x20) of (iii) tumour core and (iv) tumour margin; PARP-1 
immunohistochemistry (x20) of (v) tumour core and (vi) tumour margin showing nuclear 
immunopositivity. (B) Quantitative analysis of (i) capillary area, detected by CD31 staining; (ii) 
percentage of PARP-1 positive nuclei and (iii) percentage of Ki67 positive nuclei in tumour margin 
specimens from six patients in the Dose Expansion Cohort, plotted alongside corresponding olaparib 
concentrations (red). Stained sections were image captured on Leica Slidepath and image analysis 
performed using the HALO platform. 
 
Figure 5: In vitro validation of clinically deliverable olaparib concentrations. 
The impact of two different doses of olaparib on radiosensitivity of four primary ((i) – (iv)) and two 
established ((v) – (vi)) GBM cell lines was measured by clonogenic survival assay. Twenty-four hours 
after plating, cells were exposed to olaparib or DMSO control then irradiated (1 – 5 Gy) or sham-
irradiated one hour later. Visible colonies containing at least 50 cells were counted 14 – 21 days 
after treatment and surviving fraction calculated. The linear quadratic model was fitted using 
maximum likelihood estimation and integrated to determine the mean inactivation dose (MID) for 
each experimental condition.   
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Enrolled n=48
Stage 1 n=3
Patients who underwent surgical resection n=3/3 (100%)
Olaparib 200mg BD for 3 days prior to surgery
Stage 2 n=32
Patients  who underwent surgical resection n=11/32 (34%)
Dose Escalation Cohorts 1-5 (below)
Cohort 2
N= 4
Evaluable N=4
Olaparib 100mg once daily days 1-5 per week
+
TMZ 50mg/m2 once daily continuously
2 patients had 1 cycle
1 patient had 2 cycles 
1 patient had 3 cycles
Total number of evaluable cycles = 7
Cohort 3
N=6
Evaluable N=6
Olaparib 150mg once daily days 1-5 per week
+
TMZ 50mg/m2 once daily continuously
2 patients had 1 cycle
1 patient had 4 cycles
1 patient had 5 cycles
2 patients had 6 cycles
Total number of evaluable cycles = 23 
Cohort 4
N=9
Evaluable N=7
Olaparib 150mg once daily days 1-5 per week
+
TMZ 75mg/m2 once daily continuously
2 patients had cycle 0  (not evaluable for safety endpoint)
4 patients had 1 cycle
2 patients had 3 cycles
1 patient had 6 cycles
Total number of evaluable cycles =16
Cohort 5
N=7
Evaluable N=6
Olaparib 150mg once daily days 1-3 per week
+
TMZ 75mg/m2 once daily continuously
1 patient had cycle 0  (not evaluable for safety endpoint)
4 patients had 1 cycle
1 patient had 3 cycles
1 patient had 5 cycles
Total number of evaluable cycles = 12
Cohort 1
Enrolled N= 6
Evaluable N=6
Olaparib 100mg once daily continuously
+
TMZ 50m/m2 once daily continuously
4 patients had 1 cycle
2 patients had 6 cycles
Total number of evaluable cycles=16
Stage 2 Dose Expansion 
N=13 enrolled
N=10 evaluable
Patients who underwent surgical resection n=13/13(100%)
Patients who underwent 5-ALA guided surgical resection n=10/13 (77%)
Olaparib 150mg once daily days 1-3 per week
+
TMZ 75mg2 once daily continuously
3 patients had cycle 0 (not evaluable for safety endpoint)
6 patients had 1 cycle
3 patients had 2 cycles
1 patient had 3 cycles
Total Number of evaluable cycles= 15
Figure 2
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